Role of LKB1 and AMPK in Metformin and TZD Control of Glucose Metabolism in Liver

描述(由申请人提供)：外周组织中葡萄糖和脂肪代谢的失调是2型糖尿病的一个标志。AMP激活的蛋白激酶(AMPK)是细胞和机体代谢的主要调节者，控制糖和脂的动态平衡。AMPK被低营养、运动、脂肪因子以及广泛使用的糖尿病治疗药物二甲双胍和噻唑烷二酮(TZDS)激活。作为对这些刺激的反应，AMPK在肝脏中通过鲜为人知的机制减少糖异生和脂肪生成。我们和其他人确定丝氨酸/苏氨酸激酶LKB1是介导AMPK激活的关键上游激酶。随后，我们在成年小鼠的肝脏中创建了LKB1的基因缺失，导致肝脏AMPK活性完全丧失，并显著增加了糖异生和肝脏脂肪堆积。在这些小鼠身上，我们证明了肝脏中的LKB1是二甲双胍降低血糖水平所必需的，这是二甲双胍治疗作用所需的特定途径的第一个遗传学证据。下一个大问题是了解二甲双胍如何影响LKB1/AMPK信号，以及它们如何反过来调节葡萄糖代谢。 我们建议确定LKB1和AMPK在控制肝脏糖代谢中的作用以及在二甲双胍和TZDS的治疗作用中的作用。首先，由于除了AMPK外，LKB1还可以激活12个AMPK相关的激酶，我们将确定AMPK的丢失是否可以模拟LKB1的丢失对葡萄糖代谢的影响以及对二甲双胍或TZDS的反应。为此，我们将有条件地删除成年小鼠肝脏中的LKB1或两者的催化AMPK1基因。其次，利用来自这些小鼠的肝细胞和RNAi，我们将确定调节特定代谢过程所需的LKB1/AMPK途径的关键上游和下游成分。最后，我们将确定一些新的AMPK效应器，它们控制新陈代谢，使用独特的蛋白质组学方法的组合来纯化新的AMPK底物，以及在二甲双胍或TZD治疗后基因定义的细胞中的转录谱。这些研究将更好地阐明这两种广泛使用的2型糖尿病药物的作用机制，并为未来治疗方法的发展确定许多新的靶点。

DESCRIPTION (provided by applicant): Deregulation of glucose and lipid metabolism in peripheral tissues is a hallmark of type 2 diabetes. AMP- activated protein kinase (AMPK) is a master regulator of cellular and organismal metabolism controlling glucose and lipid homeostasis. AMPK is activated by low nutrients, exercise, adipokines, and by the widely used diabetes therapeutics metformin and the thiazolidinediones (TZDs). In response to these stimuli, AMPK acts in the liver to reduce gluconeogenesis and lipogenesis through poorly understood mechanisms. We, and others, identified the serine/threonine kinase LKB1 as the critical upstream kinase mediating AMPK activation. We subsequently created a genetic deletion of LKB1 in the liver of adult mice, which resulted in complete loss of hepatic AMPK activity and dramatically increased gluconeogenesis and hepatic lipid accumulation. Using these mice, we demonstrated that LKB1 was required in liver for metformin to lower blood glucose levels, the first genetic proof of a specific pathway being required for the therapeutic action of metformin. The next big question is to understand how metformin impinges on LKB1/AMPK signaling and how they in turn regulate glucose metabolism. We propose to determine the role of LKB1 and AMPK in the control of hepatic glucose metabolism and in the therapeutic action of metformin and TZDs. First, as LKB1 is known to activate 12 AMPK-related kinases in addition to AMPK, we will determine whether loss of AMPK alone mimics the effects of loss of LKB1 on glucose metabolism and the response to metformin or TZDs. To this end, we will conditionally delete LKB1 or both catalytic AMPK1 genes in the liver of adult mice. Second, using hepatocytes derived from these mice and RNAi, we will define the critical upstream and downstream components of the LKB1/AMPK pathway required for the regulation of specific metabolic processes. Finally, we will identify a number of new effectors of AMPK that control metabolism using a combination of unique proteomic approaches to purify novel AMPK substrates in addition to transcriptional profiling in our genetically defined cells following metformin or TZD treatment. These studies will better illuminate the mechanism of action of these two widely used type 2 diabetes modalities, as well as identifying many new targets for the development of future therapeutics.